Dysplasia

CDx Diagnostics’ ​​WATS3D Participates in Highmark, Inc. Health Plans in Delaware, Pennsylvania, and West Virginia

Retrieved on: 
星期四, 五月 19, 2022
Surgery, Medical Devices, Biotechnology, Other Health, Radiology, Managed Care, Health, General Health, Oncology, Cancer, Physician, Colon, Highmark, Science, Practice, Esophagus, Stomach, Society, Time, BE, Artificial intelligence, Esophageal cancer, Evidence-based medicine, Technology, Method, Medicare, AFS, Molecular biology, IBD, Gastrointestinal Endoscopy, Commercial, GERD, Dysplasia, ASGE, Diagnosis, Galen Partners, Intelligence, Society of American Gastrointestinal and Endoscopic Surgeons, Acquisition, Cdx, Marie Cassidy, American Society for Gastrointestinal Endoscopy, CEO, Medical imaging

WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barretts esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021.

Key Points: 
  • WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barretts esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021.
  • CDx Diagnostics is pleased to share, that effective immediately, WATS3D is now considered an in-network procedure as CDx Diagnostics participates in the Commercial and Medicare networks of these Highmark, Inc. plans.
  • Empowering physicians to preempt esophageal cancer and improve patient lives is what drives us.
  • Since 2019, the ASGE has included WATS3D in its Standards of Practice Committees guideline for the screening and surveillance of BE.

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Retrieved on: 
星期二, 五月 3, 2022
Antibody, Itch, Colitis, U.S. Securities and Exchange Commission, Standard of care, Week, AD, Private Securities Litigation Reform Act, Ulcerative colitis, Remission, Maintenance, Disability, GLOBE, UC, Company, CNTB, Safety, CA, Prevalence, Patient, Security (finance), Atopic dermatitis, Asthma, University, FDA, End organ damage, Dysplasia, Cancer, MD, Adult, Biopharma LLC, Lymphocyte, SEC, Terminology, Food and Drug Administration Amendments Act of 2007, News, CEO, Inflammation, SAN, Entrepreneurship, Connect, Progressive multifocal leukoencephalopathy, Medical imaging, Pharmaceutical industry, Vaccine, S1P1, Medicine

Additionally, reductions in lymphocyte counts amongst individuals receiving CBP-307 0.2 mg confirmed pharmacodynamic activity of CBP-307 in patients with active UC.

Key Points: 
  • Additionally, reductions in lymphocyte counts amongst individuals receiving CBP-307 0.2 mg confirmed pharmacodynamic activity of CBP-307 in patients with active UC.
  • The overall safety results in this study showed CBP-307 to be generally well tolerated in patients with moderate-to-severe UC.
  • These top-line, induction phase data demonstrate the potential for CBP-307 to provide benefit to patients living with moderate-to-severe UC, said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma.
  • Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.

Nonprofit Promotional Grants Help More than 440 Organizations

Retrieved on: 
星期一, 四月 25, 2022
Other Retail, Philanthropy, Specialty, Consumer, Other Communications, Fund Raising, Foundation, Retail, Public Relations, Investor Relations, Other Consumer, Marketing, Communications, Other Philanthropy, Awareness, 4imprint, Perspiration, Backpack, Disability in Canada, Group, Organization, Program, Goal, United Nations Foundation, London, IRS, Note, Dysplasia, London Stock Exchange, School, Public relations, Medicine

The $500 in-kind grants of nonprofit promotional items helped these organizations achieve goals, from connecting with community members to fundraising to showing volunteers appreciation.

Key Points: 
  • The $500 in-kind grants of nonprofit promotional items helped these organizations achieve goals, from connecting with community members to fundraising to showing volunteers appreciation.
  • The one by one program provides an average of five grants every business day to various religious organizations, schools, 501(c)(3) organizations and registered Canadian nonprofits.
  • Ways the nonprofit promotional item grants were used include:
    Longwood Blessings in a Backpack raises funds to provide meals to food-insecure children.
  • Over the programs history, the promotional products retailer has awarded promotional products grants to more than 9,500 nonprofit organizations to help advance their missions.

Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)

Retrieved on: 
星期二, 三月 29, 2022
Oncology, Health, Genetics, Other Science, Managed Care, Science, Biotechnology, List of life sciences, CLFS, HGD, Company, Esophageal cancer, Risk, LinkedIn, Biopsy, BE, SEC, Protecting Access to Medicare Act of 2014, Gastroesophageal reflux disease, CMS, Social Security Amendments of 1965, Centers for Medicare & Medicaid Services, Incidence, Uveal melanoma, Health, Dysplasia, View, Biology, PAMA, Securities Exchange Act of 1934, Twitter, Securities Act of 1933, DecisionDx-UM, Nasdaq, COVID-19, Castle, Physician, Center, Medicare, Drug Quality and Security Act, Disease management, Esophagus, Annual report, Instagram, Atopic dermatitis, Patient, Pharmaceutical industry, Medical device, Facebook, TISSUECYPHER® BARRETT’S ESOPHAGUS TEST, CASTLE BIOSCIENCES

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for Medicare & Medicaid Services (CMS) granted Advanced Diagnostic Laboratory Test (ADLT) status for the TissueCypher Barretts Esophagus test, effective March 24, 2022.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for Medicare & Medicaid Services (CMS) granted Advanced Diagnostic Laboratory Test (ADLT) status for the TissueCypher Barretts Esophagus test, effective March 24, 2022.
  • TissueCypher is Castles prognostic test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barretts esophagus (BE).
  • ADLT status for TissueCypher is an exciting milestone for Castle and an important step toward ensuring patients with Barretts esophagus have access to our test.
  • The TissueCypher Barretts Esophagus test is Castles precision medicine test designed to predict future development of HGD and/or esophageal cancer in patients with BE.

CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

Retrieved on: 
星期五, 二月 25, 2022
Biotechnology, General Health, Pharmaceutical, Health, MPS II, IBAT, Policy, Lists of diseases, Disorder, Tuba mirum, Glycogen storage disease, Dysplasia, Liver, MPS, NDA, Research, Incidence, University, National Medical Products Administration, Therapy, Biliary atresia, University of Massachusetts Medical School, Growth, GBM, Haemophilia, Time-invariant system, Liver transplantation, University of Massachusetts, Disease, NMPA, New Drug Application, Degenerative disease, Hunter syndrome, Hepatomegaly, Glioblastoma, Cholestatic pruritus, Quality of life, CEO, Jaundice, Alagille syndrome, LSD, Serum, Fatty liver disease, Excoriation disorder, Kidney, Bile, WuXi Biologics, Patient, Enterohepatic circulation, Liver injury, PFIC, Death, Itch, Ageing, Liver disease, FDA, Sleep deprivation, Pharmaceutical industry, Fine chemical, Alagille Syndrome (ALGS), CAN108 (maralixibat), CANbridge Pharmaceuticals Inc., Biotechnology, General Health, Pharmaceutical, Health, Alagille Syndrome (ALGS), CAN108 (maralixibat), CANbridge Pharmaceuticals Inc., ALAGILLE SYNDROME (ALGS), CAN108 (MARALIXIBAT), CANBRIDGE PHARMACEUTICALS INC.

The Early and Pilot Implementation Policy of Boao Lecheng International Medical Tourism Pilot Zone enables Chinese patients to access therapeutics that are available in other parts of the world, thereby improving the quality of life of patients, especially children.

Key Points: 
  • The Early and Pilot Implementation Policy of Boao Lecheng International Medical Tourism Pilot Zone enables Chinese patients to access therapeutics that are available in other parts of the world, thereby improving the quality of life of patients, especially children.
  • CANbridge has the exclusive license to develop and commercialize CAN108 in Greater China for three rare liver disease indications: Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA).
  • The National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for CAN108 for Alagille syndrome in China under priority review.
  • Alagille syndrome (ALGS) is an autosomal dominant multisystem disorder which can lead to end-stage liver disease and death.

New Research Shows Progression to Esophageal Cancer as Detected by WATS3D

Retrieved on: 
星期二, 二月 22, 2022
Software, Research, Hardware, Oncology, Medical Devices, Technology, Hospitals, Clinical Trials, Science, Surgery, Biotechnology, Health, Esophageal cancer, Diagnosis, Method, Gastrointestinal Endoscopy, ASGE, Physician, Time, MPH, Guideline, Artificial intelligence, AFS, Molecular biology, 3D reconstruction, Dysplasia, Cancer, Cdx, Galen Partners, Conditional sentence, BE, Interval (mathematics), MBA, Society of American Gastrointestinal and Endoscopic Surgeons, Patient, Fellowship of the Royal Colleges of Surgeons, American Society for Gastrointestinal Endoscopy, CEO, Society, Â, Marie Cassidy, Medical imaging, MD

Progression of BE patients with baseline crypt dysplasia was significantly higher, at 1.42%/patient-year (95% CI, 0%-3.01%) and progression from baseline low-grade dysplasia was the highest, at 5.79%/patient-year (95% CI, 1.02%-10.55%).

Key Points: 
  • Progression of BE patients with baseline crypt dysplasia was significantly higher, at 1.42%/patient-year (95% CI, 0%-3.01%) and progression from baseline low-grade dysplasia was the highest, at 5.79%/patient-year (95% CI, 1.02%-10.55%).
  • This publication shows for the first time that WATS3D helps to detect clinically-significant pathologic lesions and provides insight into the progression rates of BE and dysplasia to cancer, said Bill Huffnagle, CEO of CDx Diagnostics.
  • By improving detection of BE and dysplasia, WATS3D can help clinicians treat their patients and prevent cancer development.
  • WATS3D is a diagnostic platform developed by CDx Diagnostics for the detection of BE and its associated neoplastic conditions.

Global Oxygen Therapy Market Report 2021-2026: Increasing Prevalence of Various Respiratory Disorders, Such as Pneumonia, CF, Asthma, Dysplasia and Sleep Apnea Creates Positive Outlook - ResearchAndMarkets.com

Retrieved on: 
星期四, 一月 27, 2022
General Health, Medical Devices, Hospitals, Health, Medical Supplies, Oxygen, Physician, Surgeon, Pneumonia, Asthma, COVID-19, POC, Nicotine, Prevalence, Hypoxia, Research, Degenerative disease, Carbon, Cannula, Blood, Dysplasia, Efficiency, Industry, Cystic fibrosis, Sleep apnea, Smokeless tobacco, Hypoxemia, Patient, CAGR, R, Health care, Beauty salon, Hospital, Pharmaceutical industry, Potash, Growth

The "Oxygen Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oxygen Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Looking forward, the global oxygen therapy market to grow at a CAGR of around 10% during the forecast period (2021-2026).
  • Oxygen therapy, or supplemental oxygen, refers to a medical treatment that involves using an additional oxygen source to manage the blood oxygen levels and prevent carbon monoxide toxicity.
  • Additionally, the development of cost-effective, rapid and accurate oxygen therapy devices and the increasing preference for oxygen therapy among doctors, physicians, surgeons and patients are also creating a positive outlook for the market.

The Worldwide Hip Orthosis Industry is Expected to Reach $606.9 Million by 2027 - ResearchAndMarkets.com

Retrieved on: 
星期二, 一月 11, 2022
Medical Supplies, Medical Devices, Health, Surgery, Physical Therapy, Biotechnology, Ageing, Patient, Profile, Motion, Muscle, Arthritis, Injury, Hip, COVID-19, Adoption, Population, Public health emergency, Joint, Ligament, Movement, Health, Legg–Calvé–Perthes disease, Thigh, Pain, Dysplasia, Head, WHO, Accident, World Health Organization, Femur, Degenerative disease, Disorder, Dentistry, Powder metallurgy

A hip orthosis is majorly used after a hip replacement revision surgery or to treat a dislocated hip of a patient.

Key Points: 
  • A hip orthosis is majorly used after a hip replacement revision surgery or to treat a dislocated hip of a patient.
  • Hip disorders majorly affect the hip joint, impacting thigh movement and the ability to support the weight of your body.
  • Various benefits are associated with the adoption of hip orthosis devices but several patients are not enough financially strong to afford such a high cost of the treatment and hip orthosis.
  • Moreover, there is a dearth of human resources that are utilized in the manufacturing of hip orthosis products.

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

Retrieved on: 
星期二, 十二月 21, 2021
TSX Venture Exchange, Multicystic dysplastic kidney, News, GLOBE, Fortis Healthcare, No, Treatment, Autosome, Therapy, Medullary sponge kidney, Kidney, Liver disease, Health, Kidney disease, Uric acid, Sirna, Method, Hypertension, CEO, Unitary state, ADPKD, Form, ARPKD, Security (finance), Islamic Republic News Agency, U.S. Securities and Exchange Commission, Xanthine oxidase, COVID-19, Diagnosis, Diabetic nephropathy, Research, NASDAQ, Publishing, Disease, Endothelial dysfunction, Quality of life, Cardiovascular disease, Dysplasia, Polycystic kidney disease, Chronic kidney disease, Company, Patent, SEC, Cystic fibrosis, Von Hippel–Lindau disease, Coronavirus, Patient, Tuberous sclerosis, Analysis, Pharmaceutical industry, Nasdaq

The Company remains dedicated to redefining kidney disease in the future and advance our lead program XRx-008 - on behalf of individuals with progressing kidney disease due to autosomal dominant polycystic kidney disease.

Key Points: 
  • The Company remains dedicated to redefining kidney disease in the future and advance our lead program XRx-008 - on behalf of individuals with progressing kidney disease due to autosomal dominant polycystic kidney disease.
  • Polycystic Kidney Disease is characterized by an array of anatomic and physiologic abnormalities, for example hypertension, endothelial dysfunction, cardiovascular disease, liver disease, cardiovascular disease involving large, medium and small caliber blood vessels as well as other health problems are frequently encountered by patients with polycystic kidney disease.
  • Polycystic kidney disease is associated with genetic changes and described by two categories- autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).
  • ADPKD is leading cause of polycystic kidney disease is autosomal dominant polycystic kidney disease and contributes approximately 90% of all individuals.

FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®

Retrieved on: 
星期日, 十二月 19, 2021
Metastasis, Gallium, PET, Risk, PSMA, Disease, Nausea, NCCN, Prostate cancer, LinkedIn, FDA, Physician, Radiation, Lymph, Incidence, Serum, Safety, Antiandrogen, GLOBE, ADT, Injection, Cardinal Health, Lung cancer, Cancer, PSA, Degenerative disease, Prostate, CEO, MTR, Man, Osteophyte, Australian Securities Exchange, Food, Company, Skin cancer, Dizziness, TGA, Dysplasia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TLX, Patient, Recurrence, IRE, National Comprehensive Cancer Network, Diarrhea, ASX, Medical device, Medical imaging, Telix

68Ga gozetotide Injection is used for imaging prostate cancer with positron emission tomography (PET), and targets prostate specific membrane antigen (PSMA), a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells.

Key Points: 
  • 68Ga gozetotide Injection is used for imaging prostate cancer with positron emission tomography (PET), and targets prostate specific membrane antigen (PSMA), a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells.
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • Prostate cancer is the second leading cancer in men in the United States after skin cancer, with nearly 250,000 cases estimated in 2021, a significantly higher incidence than either lung cancer (119,000 new cases) or bowel cancer (80,000 new cases).
  • Prostate cancer was also the second leading cause of cancer death in U.S. men in 2020, and it is estimated that more than 34,000 men will die from their disease in 2021.5 More than 812,000 U.S. men were estimated to be living with prostate cancer in 2020.6 In 2021 the National Comprehensive Cancer Network Guidelines for prostate cancer were updated to include PSMA-PET imaging to be considered as an alternative to standard imaging of bone and soft tissue and for detection of unfavorable intermediate, high and very high risk as well as recurrent prostate cancer.